APNH.Y Stock Overview
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R11.17 |
| 52 Week High | R11.59 |
| 52 Week Low | R8.35 |
| Beta | 0.75 |
| 1 Month Change | -2.87% |
| 3 Month Change | 11.59% |
| 1 Year Change | 14.77% |
| 3 Year Change | -4.02% |
| 5 Year Change | 58.89% |
| Change since IPO | 75.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| APNH.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.6% | 0.9% | 1.2% |
| 1Y | 14.8% | 13.9% | 24.7% |
Return vs Industry: APNH.Y matched the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: APNH.Y underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| APNH.Y volatility | |
|---|---|
| APNH.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APNH.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine APNH.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 8,887 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| APNH.Y fundamental statistics | |
|---|---|
| Market cap | US$4.98b |
| Earnings (TTM) | US$254.68m |
| Revenue (TTM) | US$2.23b |
19.5x
P/E Ratio2.2x
P/S RatioIs APNH.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APNH.Y income statement (TTM) | |
|---|---|
| Revenue | R42.70b |
| Cost of Revenue | R23.49b |
| Gross Profit | R19.22b |
| Other Expenses | R14.35b |
| Earnings | R4.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 03, 2024
| Earnings per share (EPS) | 10.94 |
| Gross Margin | 45.00% |
| Net Profit Margin | 11.40% |
| Debt/Equity Ratio | 42.2% |
How did APNH.Y perform over the long term?
See historical performance and comparison